FDA Blocks New ADHD Stimulant Over Safety Concerns
The U.S. Food and Drug Administration has issued a complete response letter (CRL) for Attentex (dexmethylphenidate extended-release capsules), a novel stimulant medication for attention deficit hyperactivity disorder (ADHD) developed by Cerebrix Pharmaceuticals. The CRL — which effectively rejects the application in its current form — cites insufficient evidence that the drug's formulation adequately deters abuse and requests additional human abuse potential studies.
The decision is a significant setback for Cerebrix, which had positioned Attentex as a next-generation ADHD treatment with a proprietary abuse-deterrent technology designed to prevent the capsules from being crushed, snorted, or dissolved for injection. The company's stock dropped 38 percent in after-hours trading following the announcement.
What Made Attentex Different
Attentex was designed around Cerebrix's AbuseShield technology, which encases the active ingredient in a polymer matrix that resists physical manipulation. When attempts are made to crush the capsule contents, the matrix forms a gel that cannot be easily snorted or drawn into a syringe. The technology was intended to reduce the diversion and misuse that plague existing ADHD stimulant medications.
ADHD stimulants, including methylphenidate (Ritalin, Concerta) and amphetamine salts (Adderall), are Schedule II controlled substances with well-documented abuse potential. Diversion of prescription stimulants — particularly on college campuses — has been a growing public health concern.
Why the FDA Said No
In its complete response letter, the FDA acknowledged the clinical efficacy data for Attentex but raised three specific concerns:
- Abuse potential studies were insufficient. The agency found that while the AbuseShield technology made nasal abuse more difficult, it did not adequately deter oral abuse — simply taking more pills than prescribed — which is the most common form of stimulant misuse
- Comparative abuse liability data were lacking. The FDA requested head-to-head human abuse potential studies comparing Attentex to existing ADHD medications under controlled conditions
- Post-market surveillance plan was inadequate. The agency asked for a more robust plan to monitor real-world abuse and diversion after approval
"While we support the development of abuse-deterrent formulations for controlled substances, the bar for demonstrating meaningful abuse deterrence must be high," the FDA stated in a summary of its decision.
Reaction from the ADHD Community
The decision has drawn mixed reactions. Patient advocacy organizations expressed disappointment, noting that the ongoing nationwide shortage of ADHD medications — which has persisted since late 2022 — makes new treatment options urgently needed. The shortage has forced many patients to switch medications, visit multiple pharmacies, or go without treatment entirely.
However, addiction medicine specialists largely supported the FDA's caution. Dr. Anna Lembke, chief of the Stanford Addiction Medicine Dual Diagnosis Clinic and author of Dopamine Nation, noted that abuse-deterrent labeling can create a false sense of security that paradoxically increases prescribing without truly reducing misuse.
"The opioid crisis taught us what happens when abuse-deterrent claims are taken at face value," Dr. Lembke said. "The FDA is right to demand rigorous evidence."
What Cerebrix Does Next
Cerebrix said in a statement that it is "committed to working with the FDA to address the agency's concerns" and plans to request a Type A meeting to discuss the path forward. The additional studies requested could take 12 to 18 months to design and conduct, meaning the earliest potential approval would be late 2027 or 2028.
The company has not ruled out pursuing approval without abuse-deterrent labeling, which would simplify the regulatory pathway but remove the product's primary market differentiator. Generic versions of existing ADHD stimulants are inexpensive and widely available (when not in shortage), so Attentex would need a compelling reason for physicians to prescribe it over established options.
The Bigger Picture for ADHD Treatment
The Attentex rejection highlights the tension between two legitimate public health priorities: ensuring adequate access to ADHD medications for the estimated 10 million American adults with the condition, and preventing the misuse and diversion of stimulant drugs that can cause dependency, cardiovascular complications, and psychiatric emergencies.
Non-stimulant alternatives for ADHD exist — including atomoxetine (Strattera), viloxazine (Qelbree), and guanfacine (Intuniv) — but they are generally less effective than stimulants for most patients and are not without their own side effect profiles.
For now, ADHD patients and their physicians continue to navigate a treatment landscape constrained by shortages, regulatory complexity, and the unique challenges of managing a condition that requires controlled substances for optimal treatment.
